While pharmacological activation of CB2 has consistently demonstrated protective effects in various disease models, results from CB2 KO in conjunction with disease models have been more variable, potentially due to differences in the stage of disease progression and the specific AD model utilised. Here, CNR2 is linked to Alzheimer disease.